This is a ready-to-use report for justifying the selection of an API starting material, the point at which GMP formally begins under ICH Q7. Replace every <<FILL: ...>> placeholder with your own specifics, attach the underlying route diagram and purge data, and route it through your normal document control, review, and approval. A worked filled specimen follows the template so you can see how a completed justification reads. This is the same technical logic that supports the CMC narrative in a marketing application (commonly Module 3.2.S.2.3); confirm your regulatory submission requirements separately. Verify each cited regulation against the current source before you rely on it.
Document control header
| Field | Entry |
|---|---|
| Document title | Starting Material Selection and Justification for <<FILL: API name>> |
| Document number | <<FILL: report ID, e.g. SMJ-CMC-007>> |
| Version | <<FILL: version, e.g. 1.0>> |
| Effective date | <<FILL: effective date>> |
| Supersedes | <<FILL: prior version or "New">> |
| Document owner | <<FILL: role, e.g. Head of CMC / Process Development>> |
| API / drug substance | <<FILL: API name and code>> |
| Synthesis route reference | <<FILL: route diagram / development report number>> |
1. Purpose
This report proposes and justifies the API starting material for <<FILL: API name>>, the point in the synthesis at which manufacture comes under ICH Q7 Good Manufacturing Practice. It documents why the proposed material is an appropriate starting point under ICH Q11 principles, demonstrates that impurities introduced upstream of it are adequately controlled, and defines the specification that governs it.
2. Scope
This report covers the synthesis route from raw materials through the isolated API as described in the route reference above, and it identifies which step in that route is proposed as the API starting material. It supports the GMP boundary declared in the batch records, the validation master plan, and, where applicable, the marketing application. It does not itself validate the process; process validation is covered by <<FILL: process validation protocol / report number>>.
3. Roles
| Role | Responsibility |
|---|---|
| Process Development / CMC | Proposes the starting material, generates the purge and impurity-carryover data, and authors this report. |
| Analytical / QC | Generates the analytical data supporting the starting-material specification and the purge studies. |
| Quality Unit | Reviews and approves the GMP boundary this report establishes; confirms it is reflected consistently in batch records and the validation master plan. |
| Regulatory Affairs | Owns the regulatory negotiation of the starting material with the agency and the CMC module narrative. |
4. Route description and proposed starting material
| Field | Entry |
|---|---|
| Number of steps, raw material to API | <<FILL: e.g. 6 steps>> |
| Proposed starting material | <<FILL: name, structure reference>> |
| Step at which the starting material enters | <<FILL: e.g. step 2 of 6>> |
| Structural fragment retained in the API | <<FILL: describe the structural element of the starting material that carries through to the final API>> |
| Commercial availability / alternate suppliers | <<FILL: is the material available from more than one qualified source>> |
Describe, in narrative form, why the proposed material is a significant structural fragment of the API rather than a trivial reagent, and why the chemistry before it is reasonably excluded from the GMP boundary.
5. Impurity carryover and purge assessment
List every impurity that could form or be introduced before the proposed starting material and demonstrate, with data rather than assertion, that it is purged or controlled by the time the API is isolated.
| Pre-starting-material impurity | Origin (step, reagent) | Downstream purge step(s) | Purge factor / spiking study result | Predicted carryover vs. limit | Conclusion |
|---|---|---|---|---|---|
<<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | Controlled / Not controlled |
For each row, attach or reference the spiking study that generated the purge factor. A narrative assertion that “the process removes this impurity” without spiking data does not meet the acceptance criterion in section 7.
6. Starting material specification
| Attribute | Acceptance limit | Test method reference |
|---|---|---|
| Identity | <<FILL>> | <<FILL>> |
| Assay | <<FILL>> | <<FILL>> |
| Related substances / impurities | <<FILL>> | <<FILL>> |
| Residual solvents (if carried forward) | <<FILL>> | <<FILL>> |
| Residual metals / catalysts (if carried forward) | <<FILL>> | <<FILL>> |
| Water content (if relevant to downstream chemistry) | <<FILL>> | <<FILL>> |
The specification must be meaningful enough that a supplier change or an out-of-specification starting material lot would be detected before it reaches the GMP process.
7. Acceptance criteria
The starting-material proposal is acceptable when all of the following are true:
- The proposed material is a significant structural fragment of the API, not a fragment that disappears in the next step or a trivial reagent.
- Every impurity introduced or formed before the starting material is mapped to a downstream purge step, with spiking-study data, not narrative, showing the predicted carryover sits below the relevant impurity limit.
- The starting material carries a specification (identity, assay, relevant impurities, and any carried-forward solvents or metals) sufficient to detect an out-of-specification lot.
- Enough of the synthesis remains under GMP after the starting material that the final API’s impurity profile is genuinely controlled by GMP-governed steps, not by chemistry outside GMP.
- The GMP boundary this report establishes matches the boundary declared in the batch records and the validation master plan.
8. Deviations from the proposed boundary
Record any case where manufacturing history, a supplier audit finding, or a regulatory review comment has raised a question about the proposed boundary, and how it was resolved.
| Reference | Description | Resolution |
|---|---|---|
<<FILL: deviation, audit finding, or agency comment reference, or "None">> | <<FILL>> | <<FILL>> |
9. Conclusion
State, in one or two sentences, whether the proposed starting material is justified and accepted as the GMP boundary for this API, citing the purge data and specification that support the statement.
10. References
ICH Q7, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, Section 1 (Scope) and Table 1. ICH Q11, Development and Manufacture of Drug Substances, and the ICH Q11 Questions and Answers. ICH Q3A(R2), Impurities in New Drug Substances (reporting, identification, and qualification thresholds). ICH M7(R2), Assessment and Control of DNA Reactive (Mutagenic) Impurities, where a mutagenic impurity is addressed upstream of the starting material. EMA, Guideline on the Chemistry of Active Substances, for an EU marketing authorization: finalized March 2026 and effective 1 September 2026, this guideline restructures the chemistry documentation expected for an active substance, including a clarified definition of the active substance starting material at section 4.2.3 and expanded expectations on reprocessing, material recovery, and nitrosamine impurities. Confirm it against the ICH Q11 boundary rationale used in this report rather than treating the two as separate justifications.
Confirm the current version of each reference before issue.
11. Attachments
| No. | Attachment |
|---|---|
| 1 | Full synthesis route diagram, raw material to API |
| 2 | Spiking / purge studies supporting section 5 |
| 3 | Starting material specification and analytical method validation summaries |
| 4 | Supplier information for the starting material |
12. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL: date>> | <<FILL: author>> | Initial issue. |
13. Approvals
| Role | Name | Signature | Date |
|---|---|---|---|
| Author (Process Development / CMC) | <<FILL>> | ||
| Reviewer (Analytical / QC) | <<FILL>> | ||
| Approver (Quality Unit) | <<FILL>> | ||
| Approver (Regulatory Affairs) | <<FILL>> |
Filled specimen
The following shows the justification completed for an example five-step small-molecule synthesis. The company, compound, and data are illustrative; replace them with your own.
| Field | Entry |
|---|---|
| API | Compound X, 5-step synthesis from commercially available raw materials |
| Proposed starting material | Intermediate 2A, entering at step 2 |
| Structural fragment retained | The core bicyclic ring system of Intermediate 2A is unchanged through to the isolated API |
| Pre-SM impurity 1 | Chlorinated byproduct from step 1 halogenation; purged at step 3 crystallization; spiking study shows a purge factor reducing worst-case carryover to less than 0.01% in the isolated API against a 0.10% identification threshold; controlled |
| Pre-SM impurity 2 | Regioisomer from step 1; purged at step 3 crystallization and step 4 wash; spiking study confirms carryover below 0.02%; controlled |
| Starting material specification | Identity by IR and HPLC retention time; assay not less than 98.0%; related substances not more than 0.5% total; no residual solvent carryover relevant to downstream chemistry |
| Steps remaining under GMP | Three of five steps (steps 2 through 5), including the two crystallizations that purge the pre-SM impurities and the final isolation |
| Conclusion | Intermediate 2A is accepted as the API starting material. Both pre-SM impurities are purged below their identification threshold with spiking-study support, the specification detects an out-of-specification lot, and three GMP-controlled steps remain between the starting material and the isolated API, including both purge points |
| Approvals | Authored by Process Development, reviewed by QC, approved by the Quality Unit and Regulatory Affairs before submission |
In this example, the report does the two things an inspector or a reviewing agency actually tests: it shows the boundary is not chosen simply to shrink the GMP footprint, since two genuinely GMP-controlled purge steps remain downstream, and it backs the “purged” claim with a spiking study rather than an assertion.
Common inspection findings this report prevents
- A starting material chosen late in the route with no purge data, so pre-starting-material impurities are asserted to be controlled with no evidence.
- A starting material specification too thin to detect a supplier change or an out-of-specification lot.
- A GMP boundary in this report that does not match what the batch records or validation master plan actually declare.
- Reliance on process knowledge or “it has always worked” instead of a spiking study when defending purge claims.
- No re-justification when the route or a reagent upstream of the starting material changes.
How to adapt this report
- Set your document number, owner, and API identity in the header.
- Replace the illustrative route and impurities in sections 4 through 6 with your actual synthesis and spiking-study data.
- If the API is made by cell culture or fermentation, adapt section 4 to the cell-bank-based GMP boundary (maintenance of the working cell bank, or introduction of cells into fermentation for classical fermentation) rather than a chemical starting material.
- Confirm the GMP boundary this report establishes is reflected consistently in the batch records and the validation master plan before approval.
- Confirm every regulation in section 10 against the current published version before issue.